Osteoarthritis: FDA drafts guidance on developing drugs, devices, biologics
The FDA on Wednesday published draft guidance to help drug, device and biologic sponsors develop products to treat the underlying pathophysiology and structural progression of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.